| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of acute disseminated encephalomyelitis mimicking multiple sclerosis attack treated by plasmapheresis
|
Anlar, O.
|
|
2014
|
3 |
6 |
p. 740-
1 p.
|
artikel
|
| 2 |
Acknowledgement to Reviewers
|
|
|
2014
|
3 |
6 |
p. 668-669
2 p.
|
artikel
|
| 3 |
A large series of Toxocara canis myelitis
|
Jabbour, R.
|
|
2014
|
3 |
6 |
p. 742-
1 p.
|
artikel
|
| 4 |
A prospective study on the prognosis of multiple sclerosis in Tunisia: Do we really have a distinct disease course in North Africa?
|
Sidhom, Y.
|
|
2014
|
3 |
6 |
p. 740-741
2 p.
|
artikel
|
| 5 |
Are DMDs really more effective in CIS?
|
Zakaria, Magd
|
|
2014
|
3 |
6 |
p. 769-
1 p.
|
artikel
|
| 6 |
Assessment of multiple sclerosis awareness and knowledge among the Saudi population in Riyadh City
|
Hudaif, H.S.A.
|
|
2014
|
3 |
6 |
p. 758-
1 p.
|
artikel
|
| 7 |
Association between trigeminal neuralgia and multiple sclerosis: A population-based study
|
Koushki, M.M.
|
|
2014
|
3 |
6 |
p. 740-
1 p.
|
artikel
|
| 8 |
A study of general health status and depression in multiple sclerosis patients and its relation with some of their individual characteristics in the Urmia City, Islamic Republic of Iran
|
Mohammadzaie, N.
|
|
2014
|
3 |
6 |
p. 747-748
2 p.
|
artikel
|
| 9 |
Biomarkers of MS therapies
|
Dhib-Jalbut, Suhayl
|
|
2014
|
3 |
6 |
p. 765-
1 p.
|
artikel
|
| 10 |
Brain MRI findings in Iranian patients with optic neuritis
|
Tafakhori, Z.
|
|
2014
|
3 |
6 |
p. 745-
1 p.
|
artikel
|
| 11 |
Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis
|
Jeffery, D.
|
|
2014
|
3 |
6 |
p. 752-753
2 p.
|
artikel
|
| 12 |
Characteristics of a cohort of MS patients in Abu Dhabi
|
Schiess, N.
|
|
2014
|
3 |
6 |
p. 760-
1 p.
|
artikel
|
| 13 |
CIS diagnostics and predictors of conversion to CDMS
|
Montalban, Xavier
|
|
2014
|
3 |
6 |
p. 764-
1 p.
|
artikel
|
| 14 |
Clinical and radiologic correlates of quality of life measures in patients with relapse-onset multiple sclersosis
|
Sadaghiani, S.
|
|
2014
|
3 |
6 |
p. 762-
1 p.
|
artikel
|
| 15 |
Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a Nation-Wide Cohort
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 738-739
2 p.
|
artikel
|
| 16 |
Cognitive impairment in patients with clinically isolated syndrome
|
Moghadam, N.B.
|
|
2014
|
3 |
6 |
p. 739-740
2 p.
|
artikel
|
| 17 |
Comparative investigation of different sequences of Magnetic Resonance Imaging such as FLAIR, T2WI and PDWI in detection of Multiple Sclerosis patients referred to Magnetic Resonance Imaging Department of Imam Khomeini Hospital, Urmia, Iran
|
Mohammadzaie, N.
|
|
2014
|
3 |
6 |
p. 746-
1 p.
|
artikel
|
| 18 |
Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis
|
Radue, E.W.
|
|
2014
|
3 |
6 |
p. 750-751
2 p.
|
artikel
|
| 19 |
Cortical demyelination in MS
|
Bunyan, Reem
|
|
2014
|
3 |
6 |
p. 768-
1 p.
|
artikel
|
| 20 |
Cortical venous sinus thrombosis after LP and high dose steroid in a case clinically isolated syndrome
|
Thakre, M.
|
|
2014
|
3 |
6 |
p. 759-
1 p.
|
artikel
|
| 21 |
Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome reports with SC interferon beta-1a
|
Amor, A.F.
|
|
2014
|
3 |
6 |
p. 756-757
2 p.
|
artikel
|
| 22 |
Defining breakthrough disease: When to escalate
|
Comi, Giancarlo
|
|
2014
|
3 |
6 |
p. 764-765
2 p.
|
artikel
|
| 23 |
Demographics and clinical characteristics of pediatric onset multiple sclerosis
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 739-
1 p.
|
artikel
|
| 24 |
Diagnosis and treatment of multiple sclerosis: MENACTRIMS consensus guidelines
|
Yamout, Bassem
|
|
2014
|
3 |
6 |
p. 766-
1 p.
|
artikel
|
| 25 |
Differential diagnosis of MS
|
Montalban, Xavier
|
|
2014
|
3 |
6 |
p. 769-
1 p.
|
artikel
|
| 26 |
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome
|
Kinkel, R.P.
|
|
2014
|
3 |
6 |
p. 712-719
8 p.
|
artikel
|
| 27 |
Economic costs associated with an MS relapse
|
O׳Connell, K.
|
|
2014
|
3 |
6 |
p. 678-683
6 p.
|
artikel
|
| 28 |
Editors’ Welcome
|
Banwell, Brenda
|
|
2014
|
3 |
6 |
p. 667-
1 p.
|
artikel
|
| 29 |
Effect of natalizumab on clinical/radiological disease activity and EDSS of relapsing remitting multiple sclerosis patients
|
Agiela, M.
|
|
2014
|
3 |
6 |
p. 755-
1 p.
|
artikel
|
| 30 |
Effects of recurrent fasting on fatigue and quality of life in patients with multiple sclerosis
|
Nasr, Z.
|
|
2014
|
3 |
6 |
p. 747-
1 p.
|
artikel
|
| 31 |
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study
|
Kieseier, B.C.
|
|
2014
|
3 |
6 |
p. 756-
1 p.
|
artikel
|
| 32 |
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study
|
Montalban, X.
|
|
2014
|
3 |
6 |
p. 761-762
2 p.
|
artikel
|
| 33 |
Efficacy and safety of fingolimod treatment in multiple sclerosis: The clinical experience of the AUBMC Multiple Sclerosis Center in Lebanon
|
Yamout, B.
|
|
2014
|
3 |
6 |
p. 749-
1 p.
|
artikel
|
| 34 |
Efficacy of lower fingolimod doses in the treatment of MS
|
Yamout, B.
|
|
2014
|
3 |
6 |
p. 758-
1 p.
|
artikel
|
| 35 |
Epidemiology of MS
|
Bohlega, Saeed
|
|
2014
|
3 |
6 |
p. 766-767
2 p.
|
artikel
|
| 36 |
Epidemiology of multiple sclerosis in the Middle East: A systematic review and meta analysis
|
Nasr, Z.
|
|
2014
|
3 |
6 |
p. 744-
1 p.
|
artikel
|
| 37 |
Evaluation of circulating endothelial cell level in patients with optic neuritis attack
|
Dehghani, L.
|
|
2014
|
3 |
6 |
p. 762-763
2 p.
|
artikel
|
| 38 |
Evaluation of SNP rs763361 on Gly307Ser gene in multiple sclerosis patients compared to healthy subjects
|
Alsahebfosoul, F.
|
|
2014
|
3 |
6 |
p. 744-
1 p.
|
artikel
|
| 39 |
Fingolimod (Gilenya) may improve the chances of conception in women with multiple sclerosis (MS) associated with secondary infertlity
|
Inshasi, J.
|
|
2014
|
3 |
6 |
p. 749-750
2 p.
|
artikel
|
| 40 |
Four-year Expanded Disability Status Scale (EDSS) outcomes in patients treated with fingolimod in the Phase 3 and extension trial program
|
Cree, Bruce
|
|
2014
|
3 |
6 |
p. 751-752
2 p.
|
artikel
|
| 41 |
Genetics of MS in Saudi Arabia
|
Jumah, M.A.A.
|
|
2014
|
3 |
6 |
p. 743-744
2 p.
|
artikel
|
| 42 |
Genomic detection and characterization of a potential therapeutic biomarker in Bahraini patients with multiple sclerosis
|
Bakhiet, Moiz
|
|
2014
|
3 |
6 |
p. 767-768
2 p.
|
artikel
|
| 43 |
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis
|
La Gioia, Sara
|
|
2014
|
3 |
6 |
p. 732-734
3 p.
|
artikel
|
| 44 |
Good cardiac safety in patients with relapsing remitting multiple sclerosis upon first fingolimod dose
|
Limmroth, V.
|
|
2014
|
3 |
6 |
p. 754-
1 p.
|
artikel
|
| 45 |
HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients
|
Abolfazli, R.
|
|
2014
|
3 |
6 |
p. 743-
1 p.
|
artikel
|
| 46 |
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study
|
Lublin, Fred D.
|
|
2014
|
3 |
6 |
p. 696-704
9 p.
|
artikel
|
| 47 |
Immunology of MS
|
Khoury, Samia
|
|
2014
|
3 |
6 |
p. 766-
1 p.
|
artikel
|
| 48 |
Impact of stop β interferon on 20 cases of relapsing remitting multiple sclerosis in BMC Benghazi-Libya 2011
|
Agiela, M.
|
|
2014
|
3 |
6 |
p. 753-
1 p.
|
artikel
|
| 49 |
Inflammatory cytokines in relapsing-remitting multiple sclerosis (RRMS) patients
|
Shaharian, M.
|
|
2014
|
3 |
6 |
p. 741-
1 p.
|
artikel
|
| 50 |
Intracranial Germinoma: Very rare mimicker of multiple sclerosis
|
Inshasi, J.
|
|
2014
|
3 |
6 |
p. 745-
1 p.
|
artikel
|
| 51 |
Investigation of Oncostatin M protein expression in Iranian relapsing remitting multiple sclerosis patients
|
Alikhani, P.
|
|
2014
|
3 |
6 |
p. 747-
1 p.
|
artikel
|
| 52 |
Is multiple sclerosis more disabling in North African patients?
|
Slassi, Ilham
|
|
2014
|
3 |
6 |
p. 769-
1 p.
|
artikel
|
| 53 |
Kestenbaum׳s capillary number test - A forgotten sign?
|
Hawkes, Elizabeth D.
|
|
2014
|
3 |
6 |
p. 735-737
3 p.
|
artikel
|
| 54 |
Long-term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: Results from a phase 2 extension study
|
Jumah, M.A.
|
|
2014
|
3 |
6 |
p. 755-756
2 p.
|
artikel
|
| 55 |
Long-term safety of fingolimod: Interim evaluation of data from the longterms trial
|
Rosenstiel, P.V.
|
|
2014
|
3 |
6 |
p. 752-
1 p.
|
artikel
|
| 56 |
Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis
|
Maghzi, Amir-Hadi
|
|
2014
|
3 |
6 |
p. 720-727
8 p.
|
artikel
|
| 57 |
Mesenchymal stem cell therapy in multiple sclerosis: An updated review of the current clinical trials
|
Mirmosayyeb, O.
|
|
2014
|
3 |
6 |
p. 750-
1 p.
|
artikel
|
| 58 |
MRI in NMO: How to differentiate from MS
|
Sahraian, Mohammad
|
|
2014
|
3 |
6 |
p. 770-
1 p.
|
artikel
|
| 59 |
MRI in the management of MS
|
Filippi, Massimo
|
|
2014
|
3 |
6 |
p. 770-771
2 p.
|
artikel
|
| 60 |
MS and cancers
|
NikKhah, R.
|
|
2014
|
3 |
6 |
p. 760-
1 p.
|
artikel
|
| 61 |
MS in Egypt
|
Hashem, Saher
|
|
2014
|
3 |
6 |
p. 768-769
2 p.
|
artikel
|
| 62 |
MS in Maghrebian inhabitants and immigrants
|
Gouider, Riadh
|
|
2014
|
3 |
6 |
p. 768-
1 p.
|
artikel
|
| 63 |
MS-like presentations of HTLV-1 infection: Case-series and review of literature
|
Moghadam-Ahmadi, A.
|
|
2014
|
3 |
6 |
p. 738-
1 p.
|
artikel
|
| 64 |
Multiple sclerosis and pregnancy
|
Oreja-Guevara, Celia
|
|
2014
|
3 |
6 |
p. 770-
1 p.
|
artikel
|
| 65 |
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS
|
Lublin, Fred D.
|
|
2014
|
3 |
6 |
p. 705-711
7 p.
|
artikel
|
| 66 |
Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 753-754
2 p.
|
artikel
|
| 67 |
Neuromyelitis optica: Case reports from Oman
|
Musafir, M.A.
|
|
2014
|
3 |
6 |
p. 741-742
2 p.
|
artikel
|
| 68 |
Osteopontin and Oncostatin M increase significantly in Iranian relapsing-remitting multiple sclerosis patients
|
Alikhani, P.
|
|
2014
|
3 |
6 |
p. 759-760
2 p.
|
artikel
|
| 69 |
PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study
|
Ziemssen, T.
|
|
2014
|
3 |
6 |
p. 751-
1 p.
|
artikel
|
| 70 |
Pediatric onset multiple sclerosis patients tend to have slower disease progression
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 742-743
2 p.
|
artikel
|
| 71 |
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis
|
Stuve, O.
|
|
2014
|
3 |
6 |
p. 754-755
2 p.
|
artikel
|
| 72 |
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica
|
Berger, Joseph R.
|
|
2014
|
3 |
6 |
p. 728-731
4 p.
|
artikel
|
| 73 |
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 755-
1 p.
|
artikel
|
| 74 |
Prevalence, demographics and clinical features of multiple sclerosis in Bahrain
|
Alsharoqi, I.
|
|
2014
|
3 |
6 |
p. 761-
1 p.
|
artikel
|
| 75 |
Progression from radiologically isolated syndrome to multiple sclerosis
|
Koushki, M.M.
|
|
2014
|
3 |
6 |
p. 740-
1 p.
|
artikel
|
| 76 |
Real world use of fingolimod in patients with relapsing remitting multiple sclerosis: A retrospective study utilising the national multiple sclerosis registry in Kuwait
|
Al-Hashel, J.
|
|
2014
|
3 |
6 |
p. 748-
1 p.
|
artikel
|
| 77 |
Recent advances in MS neuroimaging
|
Filippi, Massimo
|
|
2014
|
3 |
6 |
p. 767-
1 p.
|
artikel
|
| 78 |
Remarkable response of seropositive neuromyelitis optica to rituximab therapy – First report from kingdom of Bahrain
|
Alsharoqi, I.
|
|
2014
|
3 |
6 |
p. 761-
1 p.
|
artikel
|
| 79 |
Role of adiponectin in multiple sclerosis
|
Beni, A.A.
|
|
2014
|
3 |
6 |
p. 746-
1 p.
|
artikel
|
| 80 |
Role of histamine and diamine oxidase enzyme in Multiple Sclerosis
|
Farokhi, M.
|
|
2014
|
3 |
6 |
p. 746-
1 p.
|
artikel
|
| 81 |
Role of microchimeric cells in pathogenesis of multiple sclerosis
|
Farokhi, M.
|
|
2014
|
3 |
6 |
p. 744-745
2 p.
|
artikel
|
| 82 |
Seizures and epilepsy in multiple sclerosis patients: A Tunisian study of 9 cases
|
Hdiji, O.
|
|
2014
|
3 |
6 |
p. 757-758
2 p.
|
artikel
|
| 83 |
Severe reactivation of multiple sclerosis after discontinuation of fingolimod: An IRIS-associated phenomenon
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 748-
1 p.
|
artikel
|
| 84 |
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial
|
Kappos, L.
|
|
2014
|
3 |
6 |
p. 752-
1 p.
|
artikel
|
| 85 |
Sleep quality among patients with multiple sclerosis in West Azerbaijan
|
Taghavifar, S.
|
|
2014
|
3 |
6 |
p. 763-
1 p.
|
artikel
|
| 86 |
Socio-economic aspects of the testing for antibodies in MS-patients under interferon therapy in Austria: A cost of illness study
|
Walter, Evelyn
|
|
2014
|
3 |
6 |
p. 670-677
8 p.
|
artikel
|
| 87 |
Sustained benefit of natalizumab in pediatric multiple sclerosis with breakthrough activity: A case report
|
Gebeily, S.
|
|
2014
|
3 |
6 |
p. 757-
1 p.
|
artikel
|
| 88 |
The risk of short-term relapse in patients switching from natalizumab to fingolimod
|
Alroughani, R.
|
|
2014
|
3 |
6 |
p. 748-749
2 p.
|
artikel
|
| 89 |
The vitamin D controversy (Part 1)
|
Rieckmann, Peter.
|
|
2014
|
3 |
6 |
p. 765-
1 p.
|
artikel
|
| 90 |
The vitamin D controversy – Part 2
|
Alroughani, Raed
|
|
2014
|
3 |
6 |
p. 765-766
2 p.
|
artikel
|
| 91 |
Treatment adherence and transitioning youth in pediatric multiple sclerosis
|
Lulu, Sabeen
|
|
2014
|
3 |
6 |
p. 689-695
7 p.
|
artikel
|
| 92 |
Update on disease modifying therapies in MS
|
Compston, Alastair
|
|
2014
|
3 |
6 |
p. 767-
1 p.
|
artikel
|
| 93 |
Vitamin D receptor polymorphisms and HLA-class II genotypes among Lebanese with multiple sclerosis – A pilot study
|
Yamout, B.
|
|
2014
|
3 |
6 |
p. 759-
1 p.
|
artikel
|
| 94 |
Vitamin D status and age of onset of demyelinating disease
|
Brenton, J. Nicholas
|
|
2014
|
3 |
6 |
p. 684-688
5 p.
|
artikel
|
Tijdschrift beschrijving